Hyaluronan and hyaluronidase in genitourinary tumors

Frontiers in Bioscience

Volumn 13, Issue 15, 2008, Pages 5664-5680

  Simpson, Melanie A ^a,b   Lokeshwar, Vinata B ^c  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Cancer Diagnosis; Cancer Prognosis; Hyaluronan; Hyaluronic Acid; Hyaluronidase; Infiltration; Review; Tumor Growth; Tumor Promoter; Tumor Suppressor

Indexed keywords

GLUCURONOSYLTRANSFERASE; HERMES ANTIGEN; HYALURONAN SYNTHASE; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE;

BINDING SITE; CELL CYCLE; CELL DIVISION; CELL MOTION; ENZYMOLOGY; FEMALE; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METABOLISM; METASTASIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; UROGENITAL TRACT TUMOR;

ANTIGENS, CD44; BINDING SITES; CELL CYCLE; CELL DIVISION; CELL MOVEMENT; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; MALE; NEOPLASM METASTASIS; TRANSCRIPTION, GENETIC; UROGENITAL NEOPLASMS;

EID: 52049099844     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3108     Document Type: Review

References (196)

1. Hukill, P. B. & R. A. Vidone: Histochemistry of mucus and other polysaccharides in tumors. I. Carcinoma of the bladder. Lab Invest, 14, 1624-35 (1965)
2. Fraser, J. R., T. C. Laurent & U. B. Laurent: Hyaluronan: its nature, distribution, functions and turnover. J Intern Med, 242, 27-33 (1997) (Pubitemid 27323862)
3. Toole, B. P.: Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer, 4, 528-39 (2004) (Pubitemid 38868622)
4. Rooney, P. & S. Kumar: Inverse relationship between hyaluronan and collagens in development and angiogenesis. Differentiation, 54, 1-9 (1993) (Pubitemid 23288271)
5. Toole, B. P.: Hyaluronan promotes the malignant phenotype. Glycobiology, 12, 37R-42R (2002) (Pubitemid 34567859)
6. De Klerk, D. P.: The glycosaminoglycans of normal and hyperplastic prostate. Prostate, 4, 73-81 (1983) (Pubitemid 13125542)
7. De Klerk, D. P., D. V. Lee & H. J. Human: Glycosaminoglycans of human prostatic cancer. J Urol, 131, 1008-12 (1984) (Pubitemid 14102682)
8. Lipponen, P., S. Aaltomaa, R. Tammi, M. Tammi, U. Agren & V. M. Kosma: High stromal hyaluronan level is associated with poor differentiation and metastasis in prostate cancer. Eur J Cancer, 37, 849-56 (2001) (Pubitemid 32323962)
9. Lokeshwar, V. B., D. Rubinowicz, G. L. Schroeder, E. Forgacs, J. D. Minna, N. L. Block, M. Nadji & B. L. Lokeshwar: Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in prostate cancer. J Biol Chem, 276, 11922-32 (2001)
10. Aaltomaa, S., P. Lipponen, R. Tammi, M. Tammi, J. Viitanen, J. P. Kankkunen & V. M. Kosma: Strong Stromal Hyaluronan Expression Is Associated with PSA Recurrence in Local Prostate Cancer. Urol Int, 69, 266-72 (2002) (Pubitemid 35365379)
11. Ekici, S., W. H. Cerwinka, R. Duncan, P. Gomez, F. Civantos, M. S. Soloway & V. B. Lokeshwar: Comparison of the prognostic potential of hyaluronic acid, hyaluronidase (HYAL-1), CD44v6 and microvessel density for prostate cancer. Int J Cancer, 112, 121-9 (2004) (Pubitemid 39249499)
12. Posey, J. T., M. S. Soloway, S. Ekici, M. Sofer, F. Civantos, R. C. Duncan & V. B. Lokeshwar: Evaluation of the prognostic potential of hyaluronic acid and hyaluronidase (HYAL1) for prostate cancer. Cancer Res, 63, 2638-44 (2003) (Pubitemid 36605207)
13. Konety, B. R. & R. H. Getzenberg: Urine based markers of urological malignancy. J Urol, 165, 600-11 (2001) (Pubitemid 32060487)
14. Lokeshwar, V. B., C. Obek, M. S. Soloway & N. L. Block: Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder cancer [published erratum appears in Cancer Res 1998 Jul 15;58 (14):3191]. Cancer Res, 57, 773-7 (1997) (Pubitemid 27085665)
15. Lokeshwar, V. B., G. L. Schroeder, M. G. Selzer, S. H. Hautmann, J. T. Posey, R. C. Duncan, R. Watson, L. Rose, S. Markowitz & M. S. Soloway: Bladder tumor markers for monitoring recurrence and screening comparison of hyaluronic acid-hyaluronidase and BTA-Stat tests. Cancer, 95, 61-72 (2002) (Pubitemid 34743483)
16. Lokeshwar, V. B. & M. S. Soloway: Current bladder tumor tests: does their projected utility fulfill clinical necessity? J Urol, 165, 1067-77 (2001) (Pubitemid 32210202)
17. Passerotti, C. C., A. Bonfim, J. R. Martins, M. F. Dall'Oglio, L. O. Sampaio, A. Mendes, V. Ortiz, M. Srougi, C. P. Dietrich & H. B. Nader: Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder. Eur Urol, 49, 71-5 (2006) (Pubitemid 41789958)
18. Longaker, M. T., N. S. Adzick, D. Sadigh, B. Hendin, S. E. Stair, B. W. Duncan, M. R. Harrison, R. Spendlove & R. Stern: Hyaluronic acid-stimulating activity in the pathophysiology of Wilms' tumors. J Natl Cancer Inst, 82, 135-9 (1990) (Pubitemid 20034347)
19. Lin, R. Y., P. A. Argenta, K. M. Sullivan, R. Stern & N. S. Adzick: Urinary hyaluronic acid is a Wilms' tumor marker. J Pediatr Surg, 30, 304-8 (1995)
20. Tsuchiya, N., Y. Kondo, A. Takahashi, H. Pawar, J. Qian, K. Sato, M. M. Lieber & R. B. Jenkins: Mapping and gene expression profile of the minimally overrepresented 8q24 region in prostate cancer. Am J Pathol, 160, 1799-806 (2002) (Pubitemid 34525659)
21. Gudmundsson, J., P. Sulem, A. Manolescu, L. T. Amundadottir, D. Gudbjartsson, A. Helgason, T. Rafnar, J. T. Bergthorsson, B. A. Agnarsson, A. Baker, A. Sigurdsson, K. R. Benediktsdottir, M. Jakobsdottir, J. Xu, T. Blondal, J. Kostic, J. Sun, S. Ghosh, S. N. Stacey, M. Mouy, J. Saemundsdottir, V. M. Backman, K. Kristjansson, A. Tres, A. W. Partin, M. T. Albers-Akkers, J. Godino-Ivan Marcos, P. C. Walsh, D. W. Swinkels, S. Navarrete, S. D. Isaacs, K. K. Aben, T. Graif, J. Cashy, M. Ruiz-Echarri, K. E. Wiley, B. K. Suarez, J. A. Witjes, M. Frigge, C. Ober, E. Jonsson, G. V. Einarsson, J. I. Mayordomo, L. A. Kiemeney, W. B. Isaacs, W. J. Catalona, R. B. Barkardottir, J. R. Gulcher, U. Thorsteinsdottir, A. Kong & K. Stefansson: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet (2007)
22. Haiman, C. A., N. Patterson, M. L. Freedman, S. R. Myers, M. C. Pike, A. Waliszewska, J. Neubauer, A. Tandon, C. Schirmer, G. J. McDonald, S. C. Greenway, D. O. Stram, L. Le Marchand, L. N. Kolonel, M. Frasco, D. Wong, L. C. Pooler, K. Ardlie, I. Oakley-Girvan, A. S. Whittemore, K. A. Cooney, E. M. John, S. A. Ingles, D. Altshuler, B. E. Henderson & D. Reich: Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007)
23. Yeager, M., N. Orr, R. B. Hayes, K. B. Jacobs, P. Kraft, S. Wacholder, M. J. Minichiello, P. Fearnhead, K. Yu, N. Chatterjee, Z. Wang, R. Welch, B. J. Staats, E. E. Calle, H. S. Feigelson, M. J. Thun, C. Rodriguez, D. Albanes, J. Virtamo, S. Weinstein, F. R. Schumacher, E. Giovannucci, W. C. Willett, G. Cancel-Tassin, O. Cussenot, A. Valeri, G. L. Andriole, E. P. Gelmann, M. Tucker, D. S. Gerhard, J. F. Fraumeni, Jr., R. Hoover, D. J. Hunter, S. J. Chanock & G. Thomas: Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007)
24. Camenisch, T. D., A. P. Spicer, T. Brehm-Gibson, J. Biesterfeldt, M. L. Augustine, A. Calabro, Jr., S. Kubalak, S. E. Klewer & J. A. McDonald: Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme [see comments]. J Clin Invest, 106, 349-60 (2000) (Pubitemid 30655635)
25. Misra, S., B. P. Toole & S. Ghatak: Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. J Biol Chem, 281, 34936-41 (2006) (Pubitemid 46036532)
26. Toole, B. P., A. Zoltan-Jones, S. Misra & S. Ghatak: Hyaluronan: a critical component of epithelialmesenchymal and epithelial-carcinoma transitions. Cells Tissues Organs, 179, 66-72 (2005) (Pubitemid 40976290)
27. Ghatak, S., S. Misra & B. P. Toole: Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells. J Biol Chem, 280, 8875-83 (2005) (Pubitemid 40409577)
28. Rooney, P., S. Kumar, J. Ponting & M. Wang: The role of hyaluronan in tumour neovascularization (review). Int J Cancer, 60, 632-6 (1995)
29. West, D. C. & S. Kumar: The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res, 183, 179-96 (1989) (Pubitemid 19166520)
30. Enegd, B., J. A. King, S. Stylli, L. Paradiso, A. H. Kaye & U. Novak: Overexpression of hyaluronan synthase-2 reduces the tumorigenic potential of glioma cells lacking hyaluronidase activity. Neurosurgery, 50, 1311-8. (2002) (Pubitemid 36322773)
31. Simpson, M. A.: Concurrent expression of hyaluronan biosynthetic and processing enzymes promotes growth and vascularization of prostate tumors in mice. Am J Pathol, 169, 247-57 (2006)
32. Ghatak, S., S. Misra & B. P. Toole: Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J Biol Chem, 277, 38013-20 (2002) (Pubitemid 35154652)
33. Zhu, D. & L. Y. Bourguignon: The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acidmediated functions and prostate tumor cell transformation. Cell Motil Cytoskeleton, 39, 209-22 (1998) (Pubitemid 28136563)
34. Zeng, C., B. P. Toole, S. D. Kinney, J. W. Kuo & I. Stamenkovic: Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer, 77, 396-401 (1998) (Pubitemid 28299876)
35. Ito, T., J. D. Williams, D. Fraser & A. O. Phillips: Hyaluronan attenuates transforming growth factor-beta1-mediated signaling in renal proximal tubular epithelial cells. Am J Pathol, 164, 1979-88 (2004) (Pubitemid 38669347)
36. Ito, T., J. D. Williams, D. J. Fraser & A. O. Phillips: Hyaluronan regulates transforming growth factor-beta1 receptor compartmentalization. J Biol Chem, 279, 25326-32 (2004) (Pubitemid 38756787)
37. Aruffo, A., I. Stamenkovic, M. Melnick, C. B. Underhill & B. Seed: CD44 is the principal cell surface receptor for hyaluronate. Cell, 61, 1303-13 (1990)
38. Miyake, K., C. B. Underhill, J. Lesley & P. W. Kincade: Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyaluronate recognition. J Exp Med, 172, 69-75 (1990) (Pubitemid 20217247)
39. Simpson, M. A., J. Reiland, S. R. Burger, L. T. Furcht, A. P. Spicer, T. R. Oegema, Jr. & J. B. McCarthy: Hyaluronan synthase elevation in metastatic prostate carcinoma cells correlates with hyaluronan surface retention, a prerequisite for rapid adhesion to bone marrow endothelial cells. J Biol Chem, 276, 17949-57 (2001)
40. Simpson, M. A., C. M. Wilson, L. T. Furcht, A. P. Spicer, T. R. Oegema, Jr. & J. B. McCarthy: Manipulation of hyaluronan synthase expression in prostate adenocarcinoma cells alters pericellular matrix retention and adhesion to bone marrow endothelial cells. J Biol Chem, 277, 10050-7 (2002) (Pubitemid 34968115)
41. Zhang, X. L., W. Selbi, C. de la Motte, V. Hascall & A. Phillips: Renal proximal tubular epithelial cell transforming growth factor-beta1 generation and monocyte binding. Am J Pathol, 165, 763-73 (2004) (Pubitemid 39129284)
42. Zhang, X. L., W. Selbi, C. de la Motte, V. Hascall & A. O. Phillips: Bone morphogenic protein-7 inhibits monocyte-stimulated TGF-beta1 generation in renal proximal tubular epithelial cells. J Am Soc Nephrol, 16, 79-89 (2005) (Pubitemid 43073159)
43. Gakunga, P., G. Frost, S. Shuster, G. Cunha, B. Formby & R. Stern: Hyaluronan is a prerequisite for ductal branching morphogenesis. Development, 124, 3987-97 (1997) (Pubitemid 27483326)
44. Ito, T., J. D. Williams, S. Al-Assaf, G. O. Phillips & A. O. Phillips: Hyaluronan and proximal tubular cell migration. Kidney Int, 65, 823-33 (2004) (Pubitemid 38251058)
45. Ricciardelli, C., D. L. Russell, M. P. Ween, K. Mayne, S. Suwiwat, S. Byers, V. R. Marshall, W. D. Tilley & D. J. Horsfall: Formation of Hyaluronan-and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility. J Biol Chem, 282, 10814-25 (2007) (Pubitemid 47093429)
46. Zhang, L., C. B. Underhill & L. Chen: Hyaluronan on the surface of tumor cells is correlated with metastatic behavior. Cancer Res, 55, 428-33 (1995)
47. Patel, S., P. R. Turner, C. Stubberfield, E. Barry, C. R. Rohlff, A. Stamps, E. McKenzie, K. Young, K. Tyson, J. Terrett, G. Box, S. Eccles & M. J. Page: Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. Int J Cancer, 97, 416-24 (2002) (Pubitemid 34027798)
48. Yoshihara, S., A. Kon, D. Kudo, H. Nakazawa, I. Kakizaki, M. Sasaki, M. Endo & K. Takagaki: A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett, 579, 2722-6 (2005) (Pubitemid 40615683)
49. McCarthy, J. B., E. A. Turley, C. M. Wilson, M. Price, K. M. Bullard, M. Beck & M. A. Simpson: Hyaluronan biosynthesis in prostate carcinoma growth and metastasis. In Hyaluronan: Structure, Metabolism, Biological activities, Therapeutic Applications; Chapter 4, Hyaluronan and Tumors., Editors E.A. Balasz and V.C. Hascall, (2005)
50. West, D. C., I. N. Hampson, F. Arnold & S. Kumar: Angiogenesis induced by degradation products of hyaluronic acid. Science, 228, 1324-6 (1985)
51. Deed, R., P. Rooney, P. Kumar, J. D. Norton, J. Smith, A. J. Freemont & S. Kumar: Early-response gene signalling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by nonangiogenic, high-molecular-weight hyaluronan. Int J Cancer, 71, 251-6 (1997) (Pubitemid 27252999)
52. Simpson, M. A., C. M. Wilson & J. B. McCarthy: Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am J Pathol, 161, 849-57 (2002) (Pubitemid 34988372)
53. Bharadwaj, A. G., K. Rector & M. A. Simpson: Inducible hyaluronan production reveals differential effects on prostate tumor cell growth and tumor angiogenesis. J Biol Chem, 282, 20561-72 (2007) (Pubitemid 47100011)
54. Kumar, S., D. C. West, J. M. Ponting & H. R. Gattamaneni: Sera of children with renal tumours contain low-molecular-mass hyaluronic acid. Int J Cancer, 44, 445-8 (1989) (Pubitemid 19229301)
55. Liu, N., F. Gao, Z. Han, X. Xu, C. B. Underhill & L. Zhang: Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells. Cancer Res, 61, 5207-14 (2001) (Pubitemid 32681555)
56. van Bokhoven, A., M. Varella-Garcia, C. Korch & G. J. Miller: TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res, 61, 6340-4 (2001) (Pubitemid 32783234)
57. Wight, T. N.: Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol, 14, 617-23 (2002) (Pubitemid 35247746)
58. Ricciardelli, C., K. Mayne, P. J. Sykes, W. A. Raymond, K. McCaul, V. R. Marshall & D. J. Horsfall: Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin Cancer Res, 4, 963-71 (1998) (Pubitemid 28183398)
59. Sakko, A. J., C. Ricciardelli, K. Mayne, W. D. Tilley, R. G. Lebaron & D. J. Horsfall: Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res, 61, 926-30 (2001) (Pubitemid 32174405)
60. Day, A. J. & C. A. de la Motte: Hyaluronan crosslinking: a protective mechanism in inflammation? Trends Immunol, 26, 637-43 (2005) (Pubitemid 41628196)
61. Chen, L., H. Zhang, R. W. Powers, P. T. Russell & W. J. Larsen: Covalent linkage between proteins of the interalpha-inhibitor family and hyaluronic acid is mediated by a factor produced by granulosa cells. J Biol Chem, 271, 19409-14 (1996) (Pubitemid 26271613)
62. Trojan, L., M. S. Michel, F. Rensch, D. G. Jackson, P. Alken & R. Grobholz: Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J Urol, 172, 103-7 (2004) (Pubitemid 41615048)
63. Bourrguignon, L. Y., N. Iida, C. F. Welsh, D. Zhu, A. Krongrad & D. Pasquale: Involvement of CD44 and its variant isoforms in membrane-cytoskeleton interaction, cell adhesion and tumor metastasis. J Neurooncol, 26, 201-8 (1995) (Pubitemid 26017809)
64. Naot, D., R. V. Sionov & D. Ish-Shalom: CD44: structure, function, and association with the malignant process. Adv Cancer Res, 71, 241-319 (1997) (Pubitemid 27197761)
65. Herrlich, P., H. Morrison, J. Sleeman, V. Orian-Rousseau, H. Konig, S. Weg-Remers & H. Ponta: CD44 acts both as a growth-and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci, 910, 106-18; discussion 118-20 (2000)
66. Liu, A. Y.: Expression of CD44 in prostate cancer cells. Cancer Lett, 76, 63-9 (1994) (Pubitemid 24051649)
67. De Marzo, A. M., C. Bradshaw, J. Sauvageot, J. I. Epstein & G. J. Miller: CD44 and CD44v6 downregulation in clinical prostatic carcinoma: relation to Gleason grade and cytoarchitecture. Prostate, 34, 162-8 (1998) (Pubitemid 28156605)
68. Noordzij, M. A., G. J. van Steenbrugge, N. S. Verkaik, F. H. Schroder & T. H. van der Kwast: The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin Cancer Res, 3, 805-15 (1997) (Pubitemid 27244350)
69. Kito, H., H. Suzuki, T. Ichikawa, N. Sekita, N. Kamiya, K. Akakura, T. Igarashi, T. Nakayama, M. Watanabe, K. Harigaya & H. Ito: Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate, 49, 110-5 (2001) (Pubitemid 32937806)
70. Vis, A. N., M. A. Noordzij, K. Fitoz, M. F. Wildhagen, F. H. Schroder & T. H. van der Kwast: Prognostic value of cell cycle proteins p27 (kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer. J Urol, 164, 2156-61 (2000)
71. Welsh, C. F., D. Zhu & L. Y. Bourguignon: Interaction of CD44 variant isoforms with hyaluronic acid and the cytoskeleton in human prostate cancer cells. J Cell Physiol, 164, 605-12 (1995)
72. Gadalla, H. A., N. A. Kamel, F. A. Badary & F. G. Elanany: Expression of CD44 protein in bilharzial and nonbilharzial bladder cancers. BJU Int, 93, 151-5 (2004) (Pubitemid 38112986)
73. Stavropoulos, N. E., I. Filliadis, E. Ioachim, M. Michael, E. Mermiga, K. Hastazeris & U. O. Nseyo: CD44 standard form expression as a predictor of progression in high risk superficial bladder tumors. Int Urol Nephrol, 33, 479-83 (2001)
74. Miyake, H., I. Okamoto, I. Hara, K. Gohji, K. Yamanaka, S. Arakawa, S. Kamidono & H. Saya: Highly specific and sensitive detection of malignancy in urine samples from patients with urothelial cancer by CD44v8-10/CD44v10 competitive RT-PCR. Int J Cancer, 79, 560-4 (1998) (Pubitemid 28549465)
75. Tawfik, O. W., B. Kramer, B. Shideler, M. Danley, B. F. Kimler & J. Holzbeierlein: Prognostic significance of CD44, platelet-derived growth factor receptor alpha, and cyclooxygenase 2 expression in renal cell carcinoma. Arch Pathol Lab Med, 131, 261-7 (2007)
76. Yildiz, E., G. Gokce, H. Kilicarslan, S. Ayan, O. F. Goze & E. Y. Gultekin: Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int, 93, 1087-93 (2004) (Pubitemid 38758639)
77. Maitland, N. J. & A. Collins: A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int, 96, 1219-23 (2005) (Pubitemid 41743913)
78. Collins, A. T., P. A. Berry, C. Hyde, M. J. Stower & N. J. Maitland: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 65, 10946-51 (2005) (Pubitemid 41713363)
79. Culty, M., H. A. Nguyen & C. B. Underhill: The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol, 116, 1055-62 (1992)
80. Harada, H. & M. Takahashi: CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2. J Biol Chem, 282, 5597-607 (2007) (Pubitemid 47093756)
81. Bourguignon, L. Y., P. A. Singleton, F. Diedrich, R. Stern & E. Gilad: CD44 interaction with Na+-H+ exchanger (NHE1) creates acidic microenvironments leading to hyaluronidase-2 and cathepsin B activation and breast tumor cell invasion. J Biol Chem, 279, 26991-7007 (2004) (Pubitemid 38812535)
82. Legg, J. W., C. A. Lewis, M. Parsons, T. Ng & C. M. Isacke: A novel PKC-regulated mechanism controls CD44 ezrin association and directional cell motility. Nat Cell Biol, 4, 399-407 (2002) (Pubitemid 34746157)
83. Morrison, H., L. S. Sherman, J. Legg, F. Banine, C. Isacke, C. A. Haipek, D. H. Gutmann, H. Ponta & P. Herrlich: The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev, 15, 968-80 (2001) (Pubitemid 32323547)
84. Misra, S., S. Ghatak & B. P. Toole: Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem, 280, 20310-5 (2005) (Pubitemid 40776728)
85. Turley, E. A., L. Austen, D. Moore & K. Hoare: Rastransformed cells express both CD44 and RHAMM hyaluronan receptors: only RHAMM is essential for hyaluronan-promoted locomotion. Exp Cell Res, 207, 277-82 (1993) (Pubitemid 23246799)
86. Wang, C., A. D. Thor, D. H. Moore, 2nd, Y. Zhao, R. Kerschmann, R. Stern, P. H. Watson & E. A. Turley: The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res, 4, 567-76 (1998) (Pubitemid 28193554)
87. Kong, Q. Y., J. Liu, X. Y. Chen, X. W. Wang, Y. Sun & H. Li: Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder. Oncol Rep, 10, 51-5 (2003)
88. Lin, S. L., D. Chang & S. Y. Ying: Hyaluronan stimulates transformation of androgen-independent prostate cancer. Carcinogenesis, 28, 310-20 (2007) (Pubitemid 46321846)
89. Savani, R. C., G. Cao, P. M. Pooler, A. Zaman, Z. Zhou & H. M. DeLisser: Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HAmediated motility in endothelial cell function and angiogenesis. J Biol Chem, 276, 36770-8 (2001)
90. Draffin, J. E., S. McFarlane, A. Hill, P. G. Johnston & D. J. Waugh: CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res, 64, 5702-11 (2004) (Pubitemid 39095568)
91. Weigel, P. H., V. C. Hascall & M. Tammi: Hyaluronan synthases. J Biol Chem, 272, 13997-4000 (1997) (Pubitemid 27232793)
92. Itano, N. & K. Kimata: Mammalian hyaluronan synthases. IUBMB Life, 54, 195-9 (2002) (Pubitemid 36008328)
93. Itano, N., T. Sawai, M. Yoshida, P. Lenas, Y. Yamada, M. Imagawa, T. Shinomura, M. Hamaguchi, Y. Yoshida, Y. Ohnuki, S. Miyauchi, A. P. Spicer, J. A. McDonald & K. Kimata: Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties. J Biol Chem, 274, 25085-92 (1999)
94. Golshani, R., S. H. Hautmann, V. Estrella, B. L. Cohen, C. C. Kyle, M. Manoharan, M. Jorda, M. S. Soloway & V. B. Lokeshwar: HAS1 expression in bladder cancer and its relation to urinary HA test. Int J Cancer, 120, 1712-20 (2007) (Pubitemid 46399358)
95. Evanko, S. P., J. C. Angello & T. N. Wight: Formation of hyaluronan-and versican-rich pericellular matrix is required for proliferation and migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 19, 1004-13 (1999) (Pubitemid 29177349)
96. Evanko, S. P. & T. N. Wight: Intracellular localization of hyaluronan in proliferating cells. J Histochem Cytochem, 47, 1331-42 (1999)
97. Itano, N., T. Sawai, F. Atsumi, O. Miyaishi, S. Taniguchi, R. Kannagi, M. Hamaguchi & K. Kimata: Selective expression and functional characteristics of three mammalian hyaluronan synthases in oncogenic malignant transformation. J Biol Chem, 279, 18679-87 (2004) (Pubitemid 38623291)
98. Li, S. C., G. F. Chen, P. S. Chan, H. L. Choi, S. M. Ho & F. L. Chan: Altered expression of extracellular matrix and proteinases in Noble rat prostate gland after long-term treatment with sex steroids. Prostate, 49, 58-71 (2001)
99. Terry, D. E. & A. F. Clark: Glycosaminoglycans in the three lobes of the rat prostate following castration and testosterone treatment. Biochem Cell Biol, 74, 653-8 (1996) (Pubitemid 126733766)
100. Monslow, J., J. D. Williams, D. J. Fraser, D. R. Michael, P. Foka, A. P. Kift-Morgan, D. D. Luo, C. A. Fielding, K. J. Craig, N. Topley, S. A. Jones, D. P. Ramji & T. Bowen: Sp1 and Sp3 mediate constitutive transcription of the human hyaluronan synthase 2 gene. J Biol Chem, 281, 18043-50 (2006) (Pubitemid 44035604)
101. Monslow, J., J. D. Williams, C. A. Guy, I. K. Price, K. J. Craig, H. J. Williams, N. M. Williams, J. Martin, S. L. Coleman, N. Topley, A. P. Spicer, P. R. Buckland, M. Davies & T. Bowen: Identification and analysis of the promoter region of the human hyaluronan synthase 2 gene. J Biol Chem, 279, 20576-81 (2004) (Pubitemid 38656451)
102. Monslow, J., J. D. Williams, N. Norton, C. A. Guy, I. K. Price, S. L. Coleman, N. M. Williams, P. R. Buckland, A. P. Spicer, N. Topley, M. Davies & T. Bowen: The human hyaluronan synthase genes: genomic structures, proximal promoters and polymorphic microsatellite markers. Int J Biochem Cell Biol, 35, 1272-83 (2003) (Pubitemid 36577317)
103. Kuroda, K., A. Utani, Y. Hamasaki & H. Shinkai: Upregulation of putative hyaluronan synthase mRNA by basic fibroblast growth factor and insulin-like growth factor-1 in human skin fibroblasts. J Dermatol Sci, 26, 156-60 (2001) (Pubitemid 32510724)
104. Pullen, M., K. Thomas, H. Wu & P. Nambi: Stimulation of Hyaluronan synthetase by platelet-derived growth factor bb in human prostate smooth muscle cells. Pharmacology, 62, 103-6 (2001) (Pubitemid 32149741)
105. Mohamadzadeh, M., H. DeGrendele, H. Arizpe, P. Estess & M. Siegelman: Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HAdependent primary adhesion. J Clin Invest, 101, 97-108 (1998) (Pubitemid 28058908)
106. Kao, J. J.: The NF-kappaB inhibitor pyrrolidine dithiocarbamate blocks IL-1beta induced hyaluronan synthase 1 (HAS1) mRNA transcription, pointing at NFkappaB dependence of the gene HAS1. Exp Gerontol, 41, 641-7 (2006) (Pubitemid 43867230)
107. Selbi, W., C. de la Motte, V. Hascall & A. Phillips: BMP-7 modulates hyaluronan-mediated proximal tubular cell-monocyte interaction. J Am Soc Nephrol, 15, 1199-211 (2004) (Pubitemid 38526001)
108. Selbi, W., A. J. Day, M. S. Rugg, C. Fulop, C. A. de la Motte, T. Bowen, V. C. Hascall & A. O. Phillips: Overexpression of hyaluronan synthase 2 alters hyaluronan distribution and function in proximal tubular epithelial cells. J Am Soc Nephrol, 17, 1553-67 (2006) (Pubitemid 43794658)
109. Brinck, J. & P. Heldin: Expression of recombinant hyaluronan synthase (HAS) isoforms in CHO cells reduces cell migration and cell surface CD44. Exp Cell Res, 252, 342-51 (1999) (Pubitemid 29530264)
110. August, E. M., K. L. Duncan, N. M. Malinowski & R. L. Cysyk: Inhibition of fibroblast hyaluronic acid production by suramin. Oncol Res, 5, 415-22 (1993) (Pubitemid 24178304)
111. Kakizaki, I., K. Kojima, K. Takagaki, M. Endo, R. Kannagi, M. Ito, Y. Maruo, H. Sato, T. Yasuda, S. Mita, K. Kimata & N. Itano: A novel mechanism for the inhibition of hyaluronan biosynthesis by 4-methylumbelliferone. J Biol Chem, 279, 33281-9 (2004) (Pubitemid 39062975)
112. Nakazawa, H., S. Yoshihara, D. Kudo, H. Morohashi, I. Kakizaki, A. Kon, K. Takagaki & M. Sasaki: 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol, 57, 165-70 (2006)
113. Morohashi, H., A. Kon, M. Nakai, M. Yamaguchi, I. Kakizaki, S. Yoshihara, M. Sasaki & K. Takagaki: Study of hyaluronan synthase inhibitor, 4-methylumbelliferone derivatives on human pancreatic cancer cell (KP1-NL). Biochem Biophys Res Commun, 345, 1454-9 (2006) (Pubitemid 43817894)
114. Girish, K. S. & K. Kemparaju: Inhibition of Naja naja venom hyaluronidase: role in the management of poisonous bite. Life Sci, 78, 1433-40 (2006) (Pubitemid 43233810)
115. Markovic-Housley, Z., G. Miglierini, L. Soldatova, P. J. Rizkallah, U. Muller & T. Schirmer: Crystal structure of hyaluronidase, a major allergen of bee venom. Structure, 8, 1025-35 (2000) (Pubitemid 32667466)
116. Morey, S. S., K. M. Kiran & J. R. Gadag: Purification and properties of hyaluronidase from Palamneus gravimanus (Indian black scorpion) venom. Toxicon, 47, 188-95 (2006) (Pubitemid 43148944)
117. Nagaraju, S., Y. H. Mahadeswaraswamy, K. S. Girish & K. Kemparaju: Venom from spiders of the genus Hippasa: biochemical and pharmacological studies. Comp Biochem Physiol C Toxicol Pharmacol, 144, 1-9 (2006) (Pubitemid 44301958)
118. Skov, L. K., U. Seppala, J. J. Coen, N. Crickmore, T. P. King, R. Monsalve, J. S. Kastrup, M. D. Spangfort & M. Gajhede: Structure of recombinant Ves v 2 at 2.0 Angstrom resolution: structural analysis of an allergenic hyaluronidase from wasp venom. Acta Crystallogr D Biol Crystallogr, 62, 595-604 (2006) (Pubitemid 43806637)
119. Gould, S. F. & M. H. Bernstein: The localisation of bovine sperm hyaluronidase. Differentiation, 3, 123-32 (1975)
120. Jacobson, A., M. Rahmanian, K. Rubin & P. Heldin: Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors. Int J Cancer, 102, 212-9. (2002) (Pubitemid 35222286)
121. Kovar, J. L., M. A. Johnson, W. M. Volcheck, J. Chen & M. A. Simpson: Hyaluronidase expression induces prostate tumor metastasis in an orthotopic mouse model. Am J Pathol, 169, 1415-26 (2006) (Pubitemid 351194374)
122. Lokeshwar, V. B., W. H. Cerwinka, T. Isoyama & B. L. Lokeshwar: HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor. Cancer Res, 65, 7782-9 (2005) (Pubitemid 41297253)
123. Lokeshwar, V. B., W. H. Cerwinka & B. L. Lokeshwar: HYAL1 hyaluronidase: a molecular determinant of bladder tumor growth and invasion. Cancer Res, 65, 2243-50 (2005) (Pubitemid 40490133)
124. Lokeshwar, V. B., M. J. Young, G. Goudarzi, N. Iida, A. I. Yudin, G. N. Cherr & M. G. Selzer: Identification of bladder tumor-derived hyaluronidase: its similarity to HYAL1. Cancer Res, 59, 4464-70 (1999) (Pubitemid 29418770)
125. Stern, R. & M. J. Jedrzejas: Hyaluronidases: their genomics, structures, and mechanisms of action. Chem Rev, 106, 818-39 (2006)
126. Csoka, A. B., G. I. Frost & R. Stern: The six hyaluronidase-like genes in the human and mouse genomes. Matrix Biol, 20, 499-508 (2001) (Pubitemid 33109098)
127. Franzmann, E. J., G. L. Schroeder, W. J. Goodwin, D. T. Weed, P. Fisher & V. B. Lokeshwar: Expression of tumor markers hyaluronic acid and hyaluronidase (HYAL1) in head and neck tumors. Int J Cancer, 106, 438-45 (2003) (Pubitemid 36870409)
128. Garg, A., R. A. Anderson, L. J. Zaneveld & S. Garg: Biological activity assessment of a novel contraceptive antimicrobial agent. J Androl, 26, 414-21 (2005) (Pubitemid 40628979)
129. Garg, S., K. Vermani, A. Garg, R. A. Anderson, W. B. Rencher & L. J. Zaneveld: Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent. Pharm Res, 22, 584-95 (2005) (Pubitemid 40603256)
130. Hardy, C. M., G. Clydesdale, K. J. Mobbs, J. Pekin, M. L. Lloyd, C. Sweet, G. R. Shellam & M. A. Lawson: Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH20. Reproduction, 127, 325-34 (2004) (Pubitemid 38425692)
131. Suri, A.: Sperm-based contraceptive vaccines: current status, merits and development. Expert Rev Mol Med, 7, 1-16 (2005)
132. Chow, G. & W. Knudson: Characterization of promoter elements of the human HYAL-2 gene. J Biol Chem, 280, 26904-12 (2005) (Pubitemid 41040725)
133. Lepperdinger, G., J. Mullegger & G. Kreil: Hyal2-less active, but more versatile? Matrix Biol, 20, 509-14 (2001)
134. Miller, A. D.: Identification of Hyal2 as the cellsurface receptor for jaagsiekte sheep retrovirus and ovine nasal adenocarcinoma virus. Curr Top Microbiol Immunol, 275, 179-99 (2003) (Pubitemid 36025498)
135. Csoka, A. B., G. I. Frost, T. Wong & R. Stern: Purification and microsequencing of hyaluronidase isozymes from human urine. FEBS Lett, 417, 307-10 (1997) (Pubitemid 27511610)
136. Arming, S., B. Strobl, C. Wechselberger & G. Kreil: In vitro mutagenesis of PH-20 hyaluronidase from human sperm. Eur J Biochem, 247, 810-4 (1997) (Pubitemid 27337032)
137. Botzki, A., D. J. Rigden, S. Braun, M. Nukui, S. Salmen, J. Hoechstetter, G. Bernhardt, S. Dove, M. J. Jedrzejas & A. Buschauer: L-Ascorbic acid 6-hexadecanoate, a potent hyaluronidase inhibitor. X-ray structure and molecular modeling of enzyme-inhibitor complexes. J Biol Chem, 279, 45990-7 (2004) (Pubitemid 39491592)
138. Lokeshwar, V. B., G. L. Schroeder, R. I. Carey, M. S. Soloway & N. Iida: Regulation of hyaluronidase activity by alternative mRNA splicing. J Biol Chem, 277, 33654-63 (2002)
139. Triggs-Raine, B., T. J. Salo, H. Zhang, B. A. Wicklow & M. R. Natowicz: Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci U S A, 96, 6296-300 (1999) (Pubitemid 29256659)
140. Hautmann, S., M. Toma, M. F. Lorenzo Gomez, M. G. Friedrich, T. Jaekel, U. Michl, G. L. Schroeder, H. Huland, K. P. Juenemann & V. B. Lokeshwar: Immunocyt and the HA-HAase urine tests for the detection of bladder cancer: a side-by-side comparison. Eur Urol, 46, 466-71 (2004) (Pubitemid 39200854)
141. Lokeshwar, V. B., B. L. Lokeshwar, H. T. Pham & N. L. Block: Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with prostate cancer progression. Cancer Res, 56, 651-7 (1996) (Pubitemid 26043668)
142. Lokeshwar, V. B., C. Obek, H. T. Pham, D. Wei, M. J. Young, R. C. Duncan, M. S. Soloway & N. L. Block: Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J Urol, 163, 348-56 (2000)
143. Pham, H. T., N. L. Block & V. B. Lokeshwar: Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res, 57, 778-83 (1997) (Pubitemid 27085666)
144. Schroeder, G. L., M. F. Lorenzo-Gomez, S. H. Hautmann, M. G. Friedrich, S. Ekici, H. Huland & V. Lokeshwar: A side by side comparison of cytology and biomarkers for bladder cancer detection. J Urol, 172, 1123-6 (2004) (Pubitemid 39096484)
145. Stern, M., M. T. Longaker, N. S. Adzick, M. R. Harrison & R. Stern: Hyaluronidase levels in urine from Wilms' tumor patients. J Natl Cancer Inst, 83, 1569-74 (1991)
146. Beech, D. J., A. K. Madan & N. Deng: Expression of PH-20 in normal and neoplastic breast tissue. J Surg Res, 103, 203-7 (2002) (Pubitemid 34948502)
147. Bertrand, P., M. N. Courel, C. Maingonnat, F. Jardin, H. Tilly & C. Bastard: Expression of HYAL2 mRNA, hyaluronan and hyaluronidase in B-cell non-Hodgkin lymphoma: relationship with tumor aggressiveness. Int J Cancer, 113, 207-12 (2005) (Pubitemid 39628310)
148. Bertrand, P., N. Girard, C. Duval, J. d'Anjou, C. Chauzy, J. F. Menard & B. Delpech: Increased hyaluronidase levels in breast tumor metastases. Int J Cancer, 73, 327-31 (1997) (Pubitemid 27508893)
149. Christopoulos, T. A., N. Papageorgakopoulou, D. A. Theocharis, N. S. Mastronikolis, T. A. Papadas & D. H. Vynios: Hyaluronidase and CD44 hyaluronan receptor expression in squamous cell laryngeal carcinoma. Biochim Biophys Acta, 1760, 1039-45 (2006) (Pubitemid 43867929)
150. Delpech, B., A. Laquerriere, C. Maingonnat, P. Bertrand & P. Freger: Hyaluronidase is more elevated in human brain metastases than in primary brain tumours. Anticancer Res, 22, 2423-7 (2002) (Pubitemid 34857077)
151. Godin, D. A., P. C. Fitzpatrick, A. B. Scandurro, P. C. Belafsky, B. A. Woodworth, R. G. Amedee, D. J. Beech & B. S. Beckman: PH20: a novel tumor marker for laryngeal cancer. Arch Otolaryngol Head Neck Surg, 126, 402-4 (2000) (Pubitemid 30140398)
152. Junker, N., S. Latini, L. N. Petersen & P. E. Kristjansen: Expression and regulation patterns of hyaluronidases in small cell lung cancer and glioma lines. Oncol Rep, 10, 609-16 (2003)
153. Madan, A. K., K. Yu, N. Dhurandhar, C. Cullinane, Y. Pang & D. J. Beech: Association of hyaluronidase and breast adenocarcinoma invasiveness. Oncol Rep, 6, 607-9 (1999)
154. Paiva, P., M. P. Van Damme, M. Tellbach, R. L. Jones, T. Jobling & L. A. Salamonsen: Expression patterns of hyaluronan, hyaluronan synthases and hyaluronidases indicate a role for hyaluronan in the progression of endometrial cancer. Gynecol Oncol, 98, 193-202 (2005) (Pubitemid 41019105)
155. Udabage, L., G. R. Brownlee, S. K. Nilsson & T. J. Brown: The over-expression of HAS2, Hyal-2 and CD44 is implicated in the invasiveness of breast cancer. Exp Cell Res, 310, 205-17 (2005) (Pubitemid 41393701)
156. Victor, R., C. Chauzy, N. Girard, J. Gioanni, J. d'Anjou, H. Stora De Novion & B. Delpech: Human breastcancer metastasis formation in a nude-mouse model: studies of hyaluronidase, hyaluronan and hyaluronanbinding sites in metastatic cells. Int J Cancer, 82, 77-83 (1999) (Pubitemid 29266110)
157. Csoka, A. B., G. I. Frost, H. H. Heng, S. W. Scherer, G. Mohapatra & R. Stern: The hyaluronidase gene HYAL1 maps to chromosome 3p21.2-p21.3 in human and 9F1-F2 in mouse, a conserved candidate tumor suppressor locus. Genomics, 48, 63-70 (1998) (Pubitemid 28110802)
158. Ji, L., M. Nishizaki, B. Gao, D. Burbee, M. Kondo, C. Kamibayashi, K. Xu, N. Yen, E. N. Atkinson, B. Fang, M. I. Lerman, J. A. Roth & J. D. Minna: Expression of several genes in the human chromosome 3p21.3 homozygous deletion region by an adenovirus vector results in tumor suppressor activities in vitro and in vivo. Cancer Res, 62, 2715-20 (2002) (Pubitemid 34462757)
159. Frost, G. I., G. Mohapatra, T. M. Wong, A. B. Csoka, J. W. Gray & R. Stern: HYAL1LUCA-1, a candidate tumor suppressor gene on chromosome 3p21.3, is inactivated in head and neck squamous cell carcinomas by aberrant splicing of pre-mRNA. Oncogene, 19, 870-7 (2000) (Pubitemid 30153744)
160. Stern, R.: Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris), 53, 372-82 (2005) (Pubitemid 41112071)
161. Lokeshwar, V. B. & M. G. Selzer: Differences in hyaluronic acid-mediated functions and signaling in arterial, microvessel, and vein-derived human endothelial cells [In Process Citation]. J Biol Chem, 275, 27641-9 (2000)
162. Takahashi, Y., L. Li, M. Kamiryo, T. Asteriou, A. Moustakas, H. Yamashita & P. Heldin: Hyaluronan fragments induce endothelial cell differentiation in a CD44-and CXCL1/GRO1-dependent manner. J Biol Chem, 280, 24195-204 (2005) (Pubitemid 40884909)
163. Aboughalia, A. H.: Elevation of hyaluronidase-1 and soluble intercellular adhesion molecule-1 helps select bladder cancer patients at risk of invasion. Arch Med Res, 37, 109-16 (2006) (Pubitemid 41727899)
164. Shuster, S., G. I. Frost, A. B. Csoka, B. Formby & R. Stern: Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer, 102, 192-7. (2002) (Pubitemid 35168035)
165. Hilbe, W., J. Auberger, S. Dirnhofer, T. Schmid, M. Erdel & H. C. Duba: High rate of molecular alteration in histologically tumour-free bronchial epithelium of NSCLC patients detected by multicolour fluorescence in situ hybridisation. Oncol Rep, 15, 1233-40 (2006)
166. Marsit, C. J., M. Hasegawa, T. Hirao, D. H. Kim, K. Aldape, P. W. Hinds, J. K. Wiencke, H. H. Nelson & K. T. Kelsey: Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer. Cancer Res, 64, 8702-7 (2004) (Pubitemid 39552086)
167. Pizzi, S., C. Azzoni, L. Bottarelli, N. Campanini, T. D'Adda, C. Pasquali, G. Rossi, G. Rindi & C. Bordi: RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours. J Pathol, 206, 409-16 (2005) (Pubitemid 41025343)
168. Lokeshwar, V. B., V. Estrella, L. Lopez, M. Kramer, P. Gomez, M. S. Soloway & B. L. Lokeshwar: HYAL1-v1, an alternatively spliced variant of HYAL1 hyaluronidase: a negative regulator of bladder cancer. Cancer Res, 66, 11219-27 (2006) (Pubitemid 46009950)
169. Lin, G. & R. Stern: Plasma hyaluronidase (Hyal-1) promotes tumor cell cycling. Cancer Lett, 163, 95-101. (2001) (Pubitemid 32121834)
170. Chang, N. S.: Hyaluronidase activation of c-Jun Nterminal kinase is necessary for protection of L929 fibrosarcoma cells from staurosporine-mediated cell death. Biochem Biophys Res Commun, 283, 278-86 (2001)
171. Liu, X., S. Yan, T. Zhou, Y. Terada & R. L. Erikson: The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene, 23, 763-76 (2004) (Pubitemid 38241277)
172. Hall, C. L., L. A. Lange, D. A. Prober, S. Zhang & E. A. Turley: pp60 (c-src) is required for cell locomotion regulated by the hyaluronanreceptor RHAMM. Oncogene, 13, 2213-24 (1996) (Pubitemid 26411572)
173. Zhang, S., M. C. Chang, D. Zylka, S. Turley, R. Harrison & E. A. Turley: The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem, 273, 11342-8 (1998) (Pubitemid 28204989)
174. McLean, G. W., N. O. Carragher, E. Avizienyte, J. Evans, V. G. Brunton & M. C. Frame: The role of focaladhesion kinase in cancer -a new therapeutic opportunity. Nat Rev Cancer, 5, 505-15 (2005) (Pubitemid 40942827)
175. Mitra, S. K., D. A. Hanson & D. D. Schlaepfer: Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol, 6, 56-68 (2005) (Pubitemid 40064899)
176. Mingo-Sion, A. M., P. M. Marietta, E. Koller, D. M. Wolf & C. L. Van Den Berg: Inhibition of JNK reduces G2/M transit independent of p53, leading to endoreduplication, decreased proliferation, and apoptosis in breast cancer cells. Oncogene, 23, 596-604 (2004) (Pubitemid 38175015)
177. Goss, V. L., J. V. Cross, K. Ma, Y. Qian, P. W. Mola & D. J. Templeton: SAPK/JNK regulates cdc2/cyclin B kinase through phosphorylation and inhibition of cdc25c. Cell Signal, 15, 709-18 (2003) (Pubitemid 36556075)
178. Chang, N. S.: Transforming growth factor-beta1 blocks the enhancement of tumor necrosis factor cytotoxicity by hyaluronidase Hyal-2 in L929 fibroblasts. BMC Cell Biol, 3, 8 (2002)
179. Chang, N. S., J. Doherty & A. Ensign: JNK1 physically interacts with WW domain-containing oxidoreductase (WOX1) and inhibits WOX1-mediated apoptosis. J Biol Chem, 278, 9195-202 (2003) (Pubitemid 36800401)
180. Chang, N. S., N. Pratt, J. Heath, L. Schultz, D. Sleve, G. B. Carey & N. Zevotek: Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem, 276, 3361-70 (2001)
181. Basu, A. & S. Haldar: Identification of a novel Bcl-xL phosphorylation site regulating the sensitivity of taxol-or 2-methoxyestradiol- induced apoptosis. FEBS Lett, 538, 41-7 (2003) (Pubitemid 36287422)
182. Deng, X., L. Xiao, W. Lang, F. Gao, P. Ruvolo & W. S. May, Jr.: Novel role for JNK as a stress-activated Bcl2 kinase. J Biol Chem, 276, 23681-8 (2001)
183. Hautmann, S. H., V. B. Lokeshwar, G. L. Schroeder, F. Civantos, R. C. Duncan, R. Gnann, M. G. Friedrich & M. S. Soloway: Elevated tissue expression of hyaluronic acid and hyaluronidase validates the HA-HAase urine test for bladder cancer. J Urol, 165, 2068-74. (2001)
184. Eissa, S., S. K. Kassim, R. A. Labib, I. M. El-Khouly, T. M. Ghaffer, M. Sadek, O. A. Razek & O. El-Ahmady: Detection of bladder carcinoma by combined testing of urine for hyaluronidase and cytokeratin 20 RNAs. Cancer, 103, 1356-62 (2005) (Pubitemid 40410729)
185. Green, S. K., G. Francia, C. Isidoro & R. S. Kerbel: Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther, 3, 149-59 (2004) (Pubitemid 39193689)
186. Croix, B. S., J. W. Rak, S. Kapitain, C. Sheehan, C. H. Graham & R. S. Kerbel: Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. J Natl Cancer Inst, 88, 1285-96 (1996) (Pubitemid 26301616)
187. Kerbel, R. S., B. St Croix, V. A. Florenes & J. Rak: Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. Hum Cell, 9, 257-64 (1996)
188. St Croix, B., S. Man & R. S. Kerbel: Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. Cancer Lett, 131, 35-44 (1998) (Pubitemid 28467039)
189. Smith, K. J., H. G. Skelton, G. Turiansky & K. F. Wagner: Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi's sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol, 36, 239-42 (1997) (Pubitemid 27078919)
190. Spruss, T., G. Bernhardt, H. Schonenberger & W. Schiess: Hyaluronidase significantly enhances the efficacy of regional vinblastine chemotherapy of malignant melanoma. J Cancer Res Clin Oncol, 121, 193-202 (1995)
191. Haselsberger, K., H. Radner & G. Pendl: Boron neutron capture therapy for glioblastoma: improvement of boron biodistribution by hyaluronidase. Cancer Lett, 131, 109-11 (1998) (Pubitemid 28467046)
192. Pillwein, K., R. Fuiko, I. Slavc, T. Czech, G. Hawliczek, G. Bernhardt, G. Nirnberger & U. Koller: Hyaluronidase additional to standard chemotherapy improves outcome for children with malignant brain tumors. Cancer Lett, 131, 101-8 (1998) (Pubitemid 28467045)
193. Hobarth, K., U. Maier & M. Marberger: Topical chemoprophylaxis of superficial bladder cancer with mitomycin C and adjuvant hyaluronidase. Eur Urol, 21, 206-10 (1992)
194. Maier, U. & G. Baumgartner: Metaphylactic effect of mitomycin C with and without hyaluronidase after transurethral resection of bladder cancer: randomized trial. J Urol, 141, 529-30 (1989) (Pubitemid 19089142)
195. Klocker, J., H. Sabitzer, W. Raunik, S. Wieser & J. Schumer: Combined application of cisplatin, vindesine, hyaluronidase and radiation for treatment of advanced squamous cell carcinoma of the head and neck. Am J Clin Oncol, 18, 425-8 (1995)
196. Klocker, J., H. Sabitzer, W. Raunik, S. Wieser & J. Schumer: Hyaluronidase as additive to induction chemotherapy in advanced squamous cell carcinoma of the head and neck. Cancer Lett, 131, 113-5 (1998) (Pubitemid 28467047)